Oral 12 Analysis of Exhaled Volatile Organic Compounds Reveals New Biomarkers for Irritable Bowel Syndrome

Sophia Ali Patel, MD
Sophia Ali Patel, MD

Author insight from Sophia Ali Patel, MD, Pediatric GI, Cleveland Clinic Children’s, Cleveland, OH

What’s new here and important for clinicians?
Our study examined exhaled volatile organic compounds in the breath of pediatric patients with a diagnosis of irritable bowel syndrome (IBS) and compared them to healthy children. Breath samples were analyzed by mass spectrometer, the SIFT-MS. Our preliminary clinical findings indicate that patients with IBS have a unique “breathprint” compared to healthy control children

What do patients need to know?
IBS is not associated with abnormal radiologic or endoscopic abnormalities and there is no reliable biomarker; therefore, the diagnosis currently rests entirely on clinical grounds. Unfortunately, before patients are diagnosed with IBS, they often undergo a battery of tests/procedures to rule out other causes of their symptoms. Having an objective biomarker for IBS could change the way this disease is diagnosed and save the patients from many unnecessary tests. Our results indicate that patients with IBS have differences in the volatile organic compounds in their breath compared to healthy controls. Our hope is that in the future, a simple breath sample could diagnose IBS with good accuracy.

At this point, our study is in its very early phases and will require more patients and further analysis.

Read abstract

Author Contact

Sophia Ali Patel, MD, Pediatric GI, Cleveland Clinic Children’s, Cleveland, OH

Related abstracts

P506 Understanding Gender Differences in IBS: The Role of Stress From the Social Environment
P1719 Regional Variation of Care for Irritable Bowel Syndrome in the United States
P1718 Age-Related Health Care Disparities in Patients With Irritable Bowel Syndrome: Findings From a Sample of Commercially Insured Patients
P1110 Cognitive Behavioral Self-Help for Irritable Bowel Syndrome
P1117 What Strategies Do Patients With Irritable Bowel Syndrome Continue to Use Following a 9-Week Comprehensive Self-Management Program?
P1111 Two Years on Linaclotide: Tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea

Media Interview Requests:

To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.